KEARNEY
Leading global consultancy partnership Kearney has today released new data showing revenue predictions and sentiment from senior telecommunications and consumer goods lead around the metaverse. The report also reveals that many senior leaders are still unsure what form this will take and how this will affect their businesses’ bottom lines.
The Pragmatic Leader’s Guide to the Metaverse reveals that a quarter of European consumer goods and telco leaders (25%) expect to see the metaverse account for revenues of between 5-20% by 2025, rising to more than half (52%) who expect this revenue by 2030. However, exactly how to monetise these emerging concepts remains unclear, constituting a real problem for many leaders, with 84% of telecom leaders and 64% of consumer goods leaders agreeing that companies will need to expand into new markets and channels to ensure relevance in the space.
At the higher end, almost one in 10 (9%) leaders in Europe expect between 20-50% of revenue to originate from the metaverse by 2030.
The Guide draws on qualitative analysis, leveraging insights from 167 senior telecoms and consumer goods decision-makers in companies with 1,000 to 50,000+ employees across Asia Pacific, North America and Europe.
Compared to Europe, only 10% of respondents in North America predicted that between 5-20% of revenue would stem from the metaverse by 2025. This figure then rises to 45% of respondents predicting this level of revenue by 2030.
Overall, 56% of consumer goods leaders and 59% of telco leaders in Europe see the metaverse as having a positive impact on their industry. However, one in four (24%) telco leaders were ‘very’ positive about the metaverse’s impact compared to only 3% of consumer goods professionals, showing that sentiment is still highest in the technology and communications space.
One of the biggest risks leaders associated with the metaverse was cybersecurity, with 57% of telco respondents and 63% of consumer goods European respondents citing this as a high impact risk to the metaverse. Interestingly, regulatory risk was also considered ‘high impact’ by 43% of telco respondents and 27% of consumer goods respondents.
Jesper Larsson, Partner at Kearney, comments:
“Global leaders clearly see the metaverse as a true avenue of growth over the next five to ten years, with some predictions suggesting significant levels of revenue could originate in this virtual marketplace. The key challenge, however, will be how to monetise the platform as a revenue stream.”
“Technologies enabling and supporting the use of the metaverse, such as 5G, could offer potential to overcome this monetisation challenge. Such technologies would support an increased flow of data and satisfy demand, building out the capability of this platform even as they make it more profitable. Indeed, the metaverse could be the very use case that 5G has been waiting on, to realise its true potential.”
Eric Gervet, Partner at Kearney, adds:
Where once we had been seeing positive global sentiment towards the use of the metaverse as a platform for growth and revenue, inflation and global economic slowdown have put tension on the Tech sector, which requires companies to make trade-offs and pace investments. Doubling down on AI and optimizing EBITDA has become a short-term priority versus longer term investments, at least for the very short term.”
“Companies that act now to develop a strategy for how the growth of the metaverse could impact their model will have a significant advantage over the competition in deciding which technologies, partnerships and investments will be necessary to access this revenue stream.”
ENDS
Notes to Editors
Methodology
In light of the hype surrounding the metaverse, our primary research was designed to provide a comprehensive and nuanced understanding of its potential impact on businesses and the overall readiness for the metaverse. We surveyed 167 industry leaders from Asia Pacific, North America, and Europe who hold influential positions as business executives in the telecom or consumer goods sectors. Participants were required to be currently employed at companies with a minimum of 1,000 employees and hold a position within three degrees of separation from the CEO.
About Kearney
Kearney is a leading global management consulting firm. For nearly 100 years, we have been the trusted advisor to C-suites, government bodies, and nonprofit organizations. Our people make us who we are. Driven to be the difference between a big idea and making it happen, we help our clients break through. www.kearney.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
